Unlike many startups, the Company has a strong technical and management depth in place and ready to move the process forward:

Deven McGlenn, B.S. – Chief Executive Officer
Randall J. Wagner , B.S., MBA - VP Business Development
Rachel Kravitz, Ph.D. - Director of Research
Uwe R. Müller, Ph.D. - Chief Scientific Officer
Todd Meyer, B.S. - Manager, Biological Products
Richard R. Burgess, Ph.D. – Chairman of the Board

Deven McGlenn, B.S. – Chief Executive Officer

For the last four years, Mr. McGlenn consulted Fortune 500 clients in developing enterprise-wide risk management strategies as an experienced manager for the business consulting division of Arthur Andersen. This work included: assessing risks, ranking those risks according to their urgency, identifying management gaps, assisting internal audit departments in creating new ways to review information, and teaching companies how to use risk management tools and software to sort and organize findings. When creating a company’s overall risk strategy, he also assessed the existing risk management strategy, reviewed organization infrastructure, and identified areas where the company had advantages/disadvantages in the market place. He played a key role developing technology that helps companies capture, store and share risk-related information across an organization. Mr. McGlenn also lectured, taught classes, and wrote articles promoting enterprise-wide risk strategies.

During this same timeframe, he also established NeoClone’s current business model and played a key role in moving the technology from a concept into a business.

Before joining Arthur Andersen, Mr. McGlenn was the founder and CEO of an environmental risk management firm headquartered in the Midwest. Deven has a BS in Political Science with a minor in Business Administration from Marquette University, Milwaukee, WI.

Randall J. Wagner , B.S., MBA - VP Business Development

Mr. Wagner brings to NeoClone over 23 years of direct antibody experience having developed monoclonal antibodies to difficult antigen targets (i.e. small molecules, single amino acid mutations, traditionally non-immunogenic compounds, single protein molecule modifications (methylation, phosphorylation), function neutralizing Abs, antibodies to protein complexes, and mammalian transcription factors, etc.).

Mr. Wagner has a balanced mix of 11 years in academics and 12 years in business, working at the national recognized University of Wisconsin Clinical Cancer Center as part of a biotherapeutics group investigating clinical monoclonal antibodies in combination with biological response modifiers for contractors Xoma Corportion, NeoRx, Sandoz, and the NCI.  Later he served as the director of the Medical College of Wisconsin (MCW)’s core facilities.  As director he beta tested new products for then local Pharmacia Biotechnology, now GE Healthcare, including pGEX 6P GST fusion protein vector system and the soluble phase recombinant phage antibody system (RPAS).  Results published in trade publications.   

In 1996 Mr. Wagner founded and served as CEO and CSO of ProtoPROBE, Inc. (Milwaukee, WI) a fee based custom research service operation that provided comprehensive research and development including recombinant DNA and protein, monoclonal antibody, and quantitative ELISA development.  His operation served as a troubleshooting laboratory and custom supplier for client’s using Amersham Pharmacia’s recombinant GST fusion protein system and for RPAS.  He successfully ran the business for 10 years, by serving clients like GlaxoSmithKline, Pierce Biotechnology, GenVec, Miller Brewing Company, Harvard University, University of California San Francisco, University of Texas, MD Anderson Cancer Center and others.  His work has been sited in several prestigious publications including Science with GenVec (Rockville, MD), and he has a patent with Miller Brewing Company for developing several confirmation specific non cross reacting monoclonal antibody based ELISA systems.  Since ProtoPROBE, Inc. he has spent a year each developing successful antibody strategies for start ups NuPotential LLC, a cell reprogramming company (Baton Rouge, LA) and Primorigen Biosciences, LLC, protein based microarrays (Madison, WI).   

Rachel H. Kravitz, Ph.D. – Director of Research

Dr. Kravitz has over 18 years of experience in molecular biology, virology and immunology.  She received her B.S. in Biology from Tufts University in 1989 and a Ph.D. in Microbiology from University of California, Davis in 1998. Dr. Kravitz spent the majority of her career developing animal models to study viral pathogenesis in human diseases. Dr. Kravitz joined NeoClone in 2003, developing an active research program using ABL-MYC technology for developing diagnostic and therapeutic antibodies. The research program has garnered a successful track record of procuring both NIH-funded contracts and grants to further NeoClone’s research efforts.

Uwe R. Müller, Ph.D. - Chief Scientific Officer

Prior to joining Neoclone Dr. Müller was V.P. for Applied Science at Nanosphere (Northbrook, IL), where he led the research and early development of genomic microarray-based SNP assays, as well as nanoparticle-based high-sensitivity assays for protein detection. Before joining Nanosphere Dr. Müller held the position of Technology Director at Corning, Inc., where he developed and led the Biochemistry Research Department with responsibility for the company's global research activities in the Life Sciences. Prior to joining Corning Dr. Müller was Director of Advanced Technology at Vysis, Inc. (now Abbott), where his research activities focused on DNA based diagnostics, including DNA probes for fluorescent in situ hybridization and the development of array based assay systems for genomic and expression analysis.
Dr. Müller received his B.S. degree in Biology from Justus-Liebig Universität, Germany, and his M.S. and Ph.D. degrees in Microbiology from Kansas State University, Manhattan, KS. After a postdoc in Biochemistry (University of Wisconsin, Madison) he became and Assistant and then tenured Associate Professor in the Department of Microbiology and Immunology at East Carolina University School of Medicine (Greenville, NC).

Todd Meyer, B.S. - Manager, Biological Products

Mr. Meyer has over 19 years of experience in the Biotech industry.  He received his B.S. in Zoology from the University of Wisconsin in 1989.  Mr. Meyer’s varied background has included positions at Agracetus (Middleton,WI), GeneMedicine (The Woodlands, TX), and Taconic Biotechnology (Rensselaer, NY).  Mr. Meyer joined NeoClone in 2004, bringing with him a wide background and expertise in the life sciences as well as expertise in Quality Assurance and implementing production systems.  Mr. Meyer’s experience has helped NeoClone to build and maintain a Quality Management Systems approach to production, and product management.

Richard R. Burgess, Ph.D. – Chairman of the Board

Dr. Burgess is a leading authority on bacterial transcription, RNA polymerases and transcription factors. He received his B.S. in Chemistry from Caltech in 1964 and his Ph.D. in Biochemistry and Molecular Biology with Dr. James D. Watson at Harvard University in 1969. After two years as a Helen Hay Whitney postdoctoral fellow in Geneva, Switzerland, Dick joined the faculty of the University of Wisconsin-Madison in 1971 where he is now the James D. Watson Professor of Oncology.

He has published over 190 scientific articles. He is an expert at protein purification and characterization and the use of monoclonal antibodies in biochemistry, especially in immunoaffinity chromatography. He is the Editor–in Chief of the journal Protein Expression and Purification. He was awarded the Pfizer Award in Enzyme Chemistry from the American Chemical Society in 1983, the USDA Honor Award in 1996, and the Medal of the Waksman Institute in 1999.

In 1983 Dr. Burgess spent a sabbatical year as a Guggenheim Fellow as acting research director of Genetic Systems, Inc. a young monoclonal antibody-based diagnostics company in Seattle. In 1984 he founded the University of Wisconsin Biotechnology Center, which he directed until 1996 in its growth to a thriving organization with a budget of over $4 million, over 50 employees and a new $28 million building. He has considerable business experience as a member of the Scientific Advisory Boards or Boards of Directors of six different small biotech R&D companies and biomedical investment companies. He presently raises about $400,000 each year in NIH grants for his research and manages a ten-member research team.